Business, energy, technology, markets and global industry news from Business News Today

semaglutide

PharmaDeviceNews semaglutide
Representative image: Oral metabolic drug research illustrates Novo Nordisk’s $2.6 billion Hengrui deal for once-weekly GLP-1/GIP candidate HRS-1596 in obesity and diabetes.
Pharma & Biotech

Mitotech is testing a different way to burn fat. Could MT-1101 complement GLP-1 drugs?

Mitotech will present MT-1101 obesity data comparing its mitochondrial approach with semaglutide. See what preclinical results could mean for development.

Read More
Oral semaglutide has shown that a peptide drug can succeed as a tablet, but extremely low and variable gastrointestinal absorption continues to limit oral delivery for most peptide medicines. Representative image.
Features & Analysis

Why oral peptide medicines still fail even after GLP-1 drugs broke the injection barrier

Oral semaglutide demonstrated that a peptide can become a successful tablet, but extremely low and variable gastrointestinal absorption still makes most peptides poor candidates for oral delivery.

Read More
Pharma & Biotech

Evidation GLP-1 study reveals major growth runway but exposes widening access gaps

Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.

Read More
Pharma & Biotech

Apotex Sevmia challenges Wegovy as generic GLP-1 competition begins in Canada

Read how Apotex’s Sevmia approval could reshape Canada’s semaglutide market, and why dosing, pricing and reimbursement still matter.

Read More
Representative image: Kalohexis’ 710GO obesity drug research highlights how dual MC3R/MC4R activation could reshape oral weight loss therapy beyond GLP-1 medicines.
Pharma & Biotech

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Read More
Representative image of AI-enabled liver disease research, reflecting how insitro’s CTRO-1013 MASH candidate is being studied for anti-fibrotic signals beyond liver fat reduction.
Pharma & Biotech

insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test

AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.

Read More
Representative image of obesity treatment research. Kalohexis’ 710GO data highlights growing interest in dual MC3R and MC4R activation as the next frontier in weight loss drug development.
Pharma & Biotech

Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight

GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.

Read More
Pharma & Biotech

Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval

Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.

Read More
Pharma & Biotech

Could Caliway’s CBL-514 become a metabolic add-on to semaglutide and tirzepatide?

GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.

Read More
Representative image: Generic semaglutide injection pens and diabetes-care materials illustrate Apotex’s Health Canada approval for Apo-Semaglutide Injection, a generic Ozempic equivalent that could reshape GLP-1 access and diabetes treatment affordability in Canada.
Pharma & Biotech

Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market

Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.

Read More